Difference between revisions of "Team:UiOslo Norway"

Line 16: Line 16:
 
     border-bottom: 2px dotted gold;
 
     border-bottom: 2px dotted gold;
 
     border-radius: 5px;
 
     border-radius: 5px;
 +
  }
  
 +
  .teampic {
 +
    display: block;
 +
    margin-left: auto;
 +
    margin-right: auto;
 +
    width: 40%;
 +
    margin-top: 10px;
 
   }
 
   }
  
Line 33: Line 40:
 
<h3 style="text-align: center;">UiOslo_Norway</h3>
 
<h3 style="text-align: center;">UiOslo_Norway</h3>
  
<div class="goldborder imgshadow">
+
<div class="goldborder">
<img style="margin-left: auto; margin-right: auto;  width: 30%;" src="https://static.igem.org/mediawiki/2018/b/ba/T--UiOslo_Norway--teamwin.jpg" alt="Team picture with award">
+
<img class="imgshadow teampic" src="https://static.igem.org/mediawiki/2018/b/ba/T--UiOslo_Norway--teamwin.jpg" alt="Team picture with award">
 
<h3 style="text-align:center; text-decoration: italic;">Awarded Best Diagnostic Project</br>Nominated Best Presentation</br><i style="color: gold;"class="fas fa-medal"></i></h3>
 
<h3 style="text-align:center; text-decoration: italic;">Awarded Best Diagnostic Project</br>Nominated Best Presentation</br><i style="color: gold;"class="fas fa-medal"></i></h3>
 
</div>
 
</div>

Revision as of 12:49, 7 November 2018

Fast detection of vulvovaginal Candida albicans
infections using CRISPR/dCas9

Concept graphic

UiOslo_Norway

Team picture with award

Awarded Best Diagnostic Project
Nominated Best Presentation

During their lifetime 75% of women will experience a Candida albicans infection, one of the most common vulvovaginal yeast infections. Currently there are no fast methods to detect whether an infection is caused by C. albicans. As a result, women purchase over-the-counter antimycotics without knowing the cause of their infection. This contributes to the rise of antimycotic resistance, making treatment of future infections more difficult.

Based on previous projects, UiOslo_Norway aims to develop a fast detection kit for C. albicans infections, using CRISPR/dCas9. Upon a suspected infection, a vaginal sample will be treated with glucanase to selectively lyse yeast cells walls, exposing the fungal DNA. Afterwards, modified dCas9 enzymes fused with split β-lactamase are added. Using specifically designed guideRNAs, the dCas9 complexes bind adjacently on C. albicans specific DNA sequences. This activates the β-lactamase to cleave its substrate nitrocefin, producing a colored product indicating the presence of C. albicans DNA.

Contact information: uioslonorway (at) gmail dot com